Grace Therapeutics, Inc.

Grace Therapeutics (GRCE) filed an officer departure notice on June 5, 2026, marking one red-flag 8-K event in the past 90 days with no cyber incidents detected during the same window. While the 90-day window shows limited activity, a single C-suite or board departure can signal operational transition risk that warrants deeper context. The full $49 Report extends the timeline to 12 months of 8-K history, calculates dilution risk from recent financing rounds, and applies AI risk signals to assess officer replacement patterns and capital structure vulnerability. The full $49 Report adds institutional-grade risk scoring, complete financing history, and forward-looking dilution projections that routine filings don't surface.